Key result
Quinapril improves peak GLS by ~48% and preserves LVEF in hypertensive rats versus untreated controls.
Why the study?
LV GLS has been proposed as an early imaging biomarker of cardiac mechanical dysfunction, but the impact of ACE inhibitor treatment of hypertensive heart disease on LV GLS and mechanical function required assessment.
Does quinapril improve left ventricular global longitudinal strain and mechanical function in spontaneously hypertensive rats?
Does quinapril improve left ventricular global longitudinal strain and mechanical function in spontaneously hypertensive rats?
Quinapril treatment preserves left ventricular ejection fraction and global longitudinal strain in a rat model of hypertensive heart disease over a 24-month period.
ACE inhibitor-associated GLS preservation in hypertensive rats is hypothesis-generating; human trials needed before clinical relevance.
BACKGROUND: Left ventricular (LV) global longitudinal strain (GLS) has been proposed as an early imaging biomarker of cardiac mechanical dysfunction. OBJECTIVE: To assess the impact of angiotensin-converting enzyme (ACE) inhibitor treatment of hypertensive heart disease on LV GLS and mechanical function. METHODS: The spontaneously hypertensive rat (SHR) model of hypertensive heart disease ( n = 38) was studied. A subset of SHRs received quinapril (TSHR, n = 16) from 3 months (mo). Wistar Kyoto rats (WKY, n = 13) were used as controls. Tagged cardiac MRI was performed using a 4.7 T Varian preclinical scanner. RESULTS: The SHRs had significantly lower LV ejection fraction (EF) than the WKYs at 3 mo (53.0 ± 1.7% vs. 69.6 ± 2.1%, P < 0.05), 14 mo (57.0 ± 2.5% vs. 74.4 ± 2.9%, P < 0.05) and 24 mo (50.1 ± 2.4% vs. 67.0 ± 2.0%, P < 0.01). At 24 mo, ACE inhibitor treatment was associated with significantly greater LV EF in TSHRs compared to untreated SHRs (64.2 ± 3.4% vs. 50.1 ± 2.4%, P < 0.01). Peak GLS magnitude was significantly lower in SHRs compared with WKYs at 14 months (7.5% ± 0.4% vs. 9.9 ± 0.8%, P < 0.05). At 24 months, Peak GLS magnitude was significantly lower in SHRs compared with both WKYs (6.5 ± 0.4% vs. 9.7 ± 1.0%, P < 0.01) and TSHRs (6.5 ± 0.4% vs. 9.6 ± 0.6%, P < 0.05). CONCLUSIONS: ACE inhibitor treatment curtails the decline in global longitudinal strain in hypertensive rats, with the treatment group exhibiting significantly greater LV EF and GLS magnitude at 24 mo compared with untreated SHRs.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2023) studied Hypertensive heart disease (n=51). Quinapril vs. Untreated SHRs and WKYs was evaluated on Peak global longitudinal strain (GLS) magnitude at 24 months (p=<0.05). Quinapril treatment in hypertensive rats significantly preserved peak global longitudinal strain magnitude (9.6% vs 6.5%, P<0.05) and LV ejection fraction at 24 months compared to untreated rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: